Pierre-Louis Bardonnet

Principal Scientist
Novo Nordisk A/S
Bagsvaerd, Hovedstaden, Denmark

Presentation(s):

• OC 21.1 - Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A

  Sunday, June 23, 2024
  14:45 – 15:00 ICT